Skip to main content

Salarius Pharmaceuticals, Inc. (SLRX)

NASDAQ: SLRX · IEX Real-Time Price · USD
0.838
-0.014 (-1.69%)
After-hours:Oct 22, 2021 7:59 PM EDT
0.852
-0.037 (-4.19%)
At close: Oct 22, 4:00 PM
Market Cap38.17M
Revenue (ttm)4.70M
Net Income (ttm)-8.81M
Shares Out44.76M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,320,782
Open0.880
Previous Close0.890
Day's Range0.803 - 0.890
52-Week Range0.632 - 3.500
Beta1.85
AnalystsStrong Buy
Price Target4.63 (+443.2%)
Est. Earnings DateNov 4, 2021

About SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, ...

IndustryBiotechnology
CEODavid Arthur
Employees7
Stock ExchangeNASDAQ
Ticker SymbolSLRX
Full Company Profile

Financial Performance

In 2020, SLRX's revenue was $5.23 million, an increase of 51.03% compared to the previous year's $3.47 million. Losses were -$7.35 million, 6.00% more than in 2019.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.63, which is an increase of 443.17% from the latest price.

Price Target
$4.63
(443.17% upside)
Analyst Consensus: Strong Buy

News

Salarius Pharmaceuticals and Nationwide Children's Hospital Disclose Research Findings from Presentation at 2021 AACR...

HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

2 weeks ago - GlobeNewsWire

Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference

HOUSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

2 weeks ago - GlobeNewsWire

Salarius Pharmaceuticals and Nationwide Children's Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC V...

HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...

3 weeks ago - GlobeNewsWire

Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas

HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...

3 weeks ago - GlobeNewsWire

Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership

HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

1 month ago - GlobeNewsWire

Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index

HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...

1 month ago - GlobeNewsWire

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...

1 month ago - GlobeNewsWire

Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...

1 month ago - GlobeNewsWire

Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational

HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...

2 months ago - GlobeNewsWire

4 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:MUXPHX
2 months ago - Benzinga

Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022

2 months ago - GlobeNewsWire

Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results

Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET

2 months ago - GlobeNewsWire

Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets...

Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas

3 months ago - GlobeNewsWire

Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarco...

Clinical Trial Now Expands to Nine U.S. Trial Sites Clinical Trial Now Expands to Nine U.S. Trial Sites

3 months ago - GlobeNewsWire

Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...

3 months ago - GlobeNewsWire

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET

4 months ago - GlobeNewsWire

Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an ope...

4 months ago - Benzinga

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to targ...

4 months ago - GlobeNewsWire

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET

4 months ago - GlobeNewsWire

Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone dem...

4 months ago - Benzinga

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at...

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial

4 months ago - GlobeNewsWire

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical ...

Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials

5 months ago - GlobeNewsWire

Penny Stocks On Robinhood For You May 2021 Watch List

Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:IDEXMNMD
5 months ago - PennyStocks

Salarius Pharmaceuticals: Q1 Earnings Insights

Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 72.73% year over year to ($0.06), which mis...

5 months ago - Benzinga

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat

5 months ago - GlobeNewsWire